» Articles » PMID: 30386290

Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis

Overview
Journal Front Neurol
Specialty Neurology
Date 2018 Nov 3
PMID 30386290
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidence implicates involvement of the innate immune system in the initiation and progression of Parkinson's disease (PD). Monocytes and monocyte-derived cells perform a number of functions, such as phagocytosis, chemotaxis, and cytokine secretion, which may be particularly relevant to PD pathology. The behavior of these cells in early-moderate disease, in conditions more similar to the environment has not been fully evaluated. Does monocyte function, including phagocytosis, chemotaxis and cytokine secretion, differ in early-moderate PD compared to age and gender-matched controls? Participants included PD patients ( = 41) with early-moderate stage disease (Hoehn and Yahr ≤2) and age and gender matched controls ( = 41). Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood and monocytes were further separated using CD14 magnetic beads. Functional assays, including bead phagocytosis (in standard medium and autologous serum), Boyden chamber trans-well chemotaxis, and cytokine secretion on lipopolysaccharide stimulation were performed. Monocyte surface markers relating to chemotaxis were measured using immunohistochemistry and flow cytometry. Between-group analysis was performed using paired -tests. An autologous serum environment significantly increased bead phagocytosis compared to standard medium as expected, in both patients and controls. When in autologous serum, PD monocytes demonstrated enhanced phagocytosis compared to control monocytes ( = 0.029). The level of serum-based phagocytosis was influenced by complement inactivation and the origin of the serum. There were no significant differences between PD and controls in terms of standard medium based monocyte migration or cytokine secretion in this cohort. Autologous serum has a significant influence on monocyte phagocytosis and reveals increased phagocytic capacity in early-moderate PD compared to controls. These conditions may better reflect the function of monocytes in PD patients than standard medium based phagocytosis assays. Further studies will be required to replicate these results in larger cohorts, including earlier and later stages of disease, and to understand which serum factors are responsible for this observation and the potential mechanistic relevance to PD pathogenesis.

Citing Articles

Immune mechanisms and shared immune targets in neurodegenerative diseases.

Weiner H Nat Rev Neurol. 2024; 21(2):67-85.

PMID: 39681722 DOI: 10.1038/s41582-024-01046-7.


The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson's disease.

Jiao F, Zhou L, Wu Z Neurol Sci. 2024; 46(2):561-578.

PMID: 39546084 PMC: 11772541. DOI: 10.1007/s10072-024-07878-x.


Development and Validation of a Nomogram Based on Inflammatory Markers for Risk Prediction in Meige Syndrome Patients.

Fu R, Lian W, Zhang B, Liu G, Feng X, Zhu Y J Inflamm Res. 2024; 17:7721-7731.

PMID: 39473982 PMC: 11520914. DOI: 10.2147/JIR.S481649.


The immune system in Parkinson's disease: what we know so far.

Roodveldt C, Bernardino L, Oztop-Cakmak O, Dragic M, Fladmark K, Ertan S Brain. 2024; 147(10):3306-3324.

PMID: 38833182 PMC: 11449148. DOI: 10.1093/brain/awae177.


Causal relationship between immune cells and neurodegenerative diseases: a two-sample Mendelian randomisation study.

Tang C, Lei X, Ding Y, Yang S, Ma Y, He D Front Immunol. 2024; 15:1339649.

PMID: 38348026 PMC: 10859421. DOI: 10.3389/fimmu.2024.1339649.


References
1.
Gardai S, Mao W, Schule B, Babcock M, Schoebel S, Lorenzana C . Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One. 2013; 8(8):e71634. PMC: 3751933. DOI: 10.1371/journal.pone.0071634. View

2.
Goldknopf I, Sheta E, Bryson J, Folsom B, Wilson C, Duty J . Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun. 2006; 342(4):1034-9. DOI: 10.1016/j.bbrc.2006.02.051. View

3.
Williams-Gray C, Wijeyekoon R, Scott K, Hayat S, Barker R, Jones J . Abnormalities of age-related T cell senescence in Parkinson's disease. J Neuroinflammation. 2018; 15(1):166. PMC: 5972443. DOI: 10.1186/s12974-018-1206-5. View

4.
Harms A, Thome A, Yan Z, Schonhoff A, Williams G, Li X . Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp Neurol. 2017; 300:179-187. PMC: 5759972. DOI: 10.1016/j.expneurol.2017.11.010. View

5.
Bernardo J, Billingslea A, Ortiz M, Seetoo K, Macauley J, Simons E . Adherence-dependent calcium signaling in monocytes: induction of a CD14-high phenotype, stimulus-responsive subpopulation. J Immunol Methods. 1998; 209(2):165-75. DOI: 10.1016/s0022-1759(97)00157-9. View